Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer -- Lohrisch et al., 10.1200/JC

New Warnings to Avastin - nasal septum perforation - RPLS

September 26, 2006 — The US Food and Drug Administration (FDA) and
> Genentech, Inc, have notified healthcare professionals regarding
> safety labeling revisions for bevacizumab injection (Avastin) that
> warn of potential risks for reversible posterior leukoencephalopathy
> syndrome (RPLS) and nasal septum perforation associated with its use.

Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer

Outcomes of women with metachronous breast and ovarian carcinomas

2006 Commentary: Dr Steven Piver - Treatment of Ovarian Cancer at the Crossroads: 50 years after single-agent Melphalan Chemotherapy

ESO - Increasing Doctor-Patient Partnerships the Future of Cancer Care

Follow-up Care: Q & A - National Cancer Institute

Long-Term Survival of Patients with Apparent Early-Stage (FIGO I-II) Epithelial Ovarian Cancer: A Population-Based Study

Historical Progress in the Initital Management of Ovarian Cancer: Intraperitoneal Chemotherapy

004 Controversies in Patient Management: Oncology and Hospice Care

Emotional Distress in Cancer Patients: the 6th vital sign Tom Baker Cancer Centre (Calgary)/ Memorial Sloan

Gynecologic Oncology : Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulke